Panacea Biotec, India’s highly progressive research based health management company has entered into a strategic alliance with Kremers Urban Inc. (part of UCB Group) for 11 high barriers to entry generics, whose market size in US at the innovator level is around $4 billion.
The first product in this portfolio to reach the market is Tacrolimus Capsules that is being launched in US in Nov 2012. The company was granted approval of the product from United States Food and Drug Administration (US FDA) in September 2012.
Tacrolimus Capsules is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received organ transplants.
Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
